Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 112.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,629 shares of the medical research company's stock after purchasing an additional 2,975 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Charles River Laboratories International were worth $1,039,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its position in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the last quarter. GeoWealth Management LLC grew its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at about $48,000. Finally, Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after buying an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 4.2 %

Shares of Charles River Laboratories International stock opened at $107.00 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a 50 day moving average price of $149.12 and a 200 day moving average price of $172.68. The company has a market capitalization of $5.26 billion, a P/E ratio of 713.33, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the business earned $2.46 earnings per share. The business's revenue was down 1.1% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on CRL shares. UBS Group reaffirmed a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. JPMorgan Chase & Co. cut their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Finally, Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $182.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.